Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003671 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia
A Phase 2 study of Leukemia, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 20
- Study locations
NCT00003671 is a Phase 2 study of Leukemia that has completed, run by Children's Oncology Group. The registered enrollment target is 59 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT00003671, a Phase 2 study of Leukemia, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have newly diagnosed acute lymphocytic leukemia.
Conditions Studied
Interventions
- DRUG cyclophosphamide
- DRUG dexamethasone
- DRUG cytarabine
- DRUG asparaginase
- DRUG daunorubicin hydrochloride
Study Locations (20)
California
- Lucile Packard Children's Hospital at Stanford - Palo Alto
- Sutter Cancer Center - Sacramento
- Kaiser Permanente-Southern California Permanente Medical Group - San Diego
- Naval Medical Center - San Diego - San Diego
- Kaiser Permanente Medical Center - Santa Clara - Santa Clara
Florida
- Nemours Children's Clinic - Jacksonville
- Sylvester Cancer Center, University of Miami - Miami
- Baptist Hospital of Miami - Miami
- Walt Disney Memorial Cancer Institute - Orlando
- St. Mary's Hospital - West Palm Beach
Illinois
- Rush-Presbyterian-St. Luke's Medical Center - Chicago
- Children's Memorial Hospital, Chicago - Chicago
- Christ Hospital - Oak Lawn
- Saint Jude Midwest Affiliate - Peoria
Arizona
- Arizona Cancer Center - Tucson
Georgia
- Emory University Hospital - Atlanta - Atlanta
Hawaii
- Tripler Army Medical Center - Honolulu
Kansas
- Via Christi Regional Medical Center-Saint Francis Campus - Wichita
Louisiana
- Tulane University School of Medicine - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 1998-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003671
The ClinicalTrials.gov registry entry for NCT00003671 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (88% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leukemia appearing as the primary indexed condition, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003671 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT00003671 about?
NCT00003671 is a clinical study titled "Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia". RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating children who have newly diagno...
What is the current status of trial NCT00003671?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 1998-12. Estimated completion is 2009-02.
What conditions does trial NCT00003671 study?
This clinical trial studies the following conditions: Leukemia.
What interventions are being tested in trial NCT00003671?
The interventions under investigation include: cyclophosphamide (DRUG), dexamethasone (DRUG), cytarabine (DRUG), asparaginase (DRUG), daunorubicin hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00003671?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003671 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
RECRUITING · Phase 2
-
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
RECRUITING · Phase 2
-
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
RECRUITING · Phase 2
-
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
RECRUITING · Phase 2
-
A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.